AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10220795 — intervention group
Group type: COMPARATOR
Intervention: Chronic hepatitis C (CH‐C)
Number of subjects: 26
Study 10220795 — intervention group
Group type: COMPARATOR
Intervention: Large bile duct obstruction
Number of subjects: 26
Study 10513459 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (three patterns of delivery)
Number of subjects: 31
Study 10513459 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 31
Study 1907555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 ointment (1 microgram g-1) applied topically for 24 hours
Number of subjects: 0
Study 1907555 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3 (10(-8) mol l-1) applied to cultured human keratinocytes for more than 9 days
Number of subjects: 0
Study 6749271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 60
Study 6749271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31814064 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensite NavX system
Number of subjects: 30
Study 31814064 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 30
Study 31814064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 31531421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine liposomal infusion only
Number of subjects: 0
Study 31531421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine plus epinephrine liposomal infusion
Number of subjects: 0
Study 31531421 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 0
Study 28411507 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 criteria for hypomania/mania with mixed features
Number of subjects: 482
Study 28411507 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-5 criteria for depressive episode with mixed features
Number of subjects: 482
Study 28411507 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mixed features in patients with mania/hypomania
Number of subjects: 482
Study 28411507 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mixed features in patients with depression
Number of subjects: 482
Study 28411507 — intervention group
Group type: COMPARATOR
Intervention: DSM-IV mixed episodes diagnoses
Number of subjects: 482
Study 28411507 — intervention group
Group type: COMPARATOR
Intervention: BISS assessment for mixed episodes
Number of subjects: 482
Study 23567655 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 6729
Study 20619353 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 68
Study 20619353 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 50 μg
Number of subjects: 68
Study 20619353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18963991 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD children
Number of subjects: 0
Study 18963991 — intervention group
Group type: COMPARATOR
Intervention: Children with cerebellar lesions
Number of subjects: 0
Study 18963991 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 17726315 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased consumption of vegetables (V)
Number of subjects: 57
Study 17726315 — intervention group
Group type: COMPARATOR
Intervention: Increased consumption of cereals (C)
Number of subjects: 57
Study 14972424 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Warfarin (1.25mg of warfarin plus 75mg of aspirin)
Number of subjects: 3300
Study 14972424 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75mg)
Number of subjects: 3300
Study 11502526 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinafloxacin (single oral doses)
Number of subjects: 64
Study 9210065 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) with cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Number of subjects: 9
Study 9210065 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) alone
Number of subjects: 9
Study 9210065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (4 g/course, 1 to 9 courses every 4 weeks)
Number of subjects: 9
Study 9210065 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responder patients)
Number of subjects: 9
Study 8425424 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection and primary anastomosis in Group A
Number of subjects: 31
Study 8425424 — intervention group
Group type: COMPARATOR
Intervention: Mesosigmoidopexy in Group A
Number of subjects: 31
Study 8425424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hartmann's procedure in Group B
Number of subjects: 31
Study 8425424 — intervention group
Group type: COMPARATOR
Intervention: Resection and primary anastomosis in Group B
Number of subjects: 31
Study 3305464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 110
Study 3305464 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin/Tobramycin
Number of subjects: 110
Study 31559434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 1294
Study 29458399 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Kinesiotape (AcuKT)
Number of subjects: 60
Study 29458399 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture alone
Number of subjects: 60
Study 28242265 — intervention group
Group type: EXPERIMENTAL
Intervention: Free quadriceps tendon autograft
Number of subjects: 48
Study 28242265 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon autograft
Number of subjects: 48
Study 24547956 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 96
Study 24547956 — intervention group
Group type: COMPARATOR
Intervention: Control group (Corticosteroids)
Number of subjects: 96
Study 22545585 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use-as-coping
Number of subjects: 0
Study 22545585 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 0
Study 19660844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of casein
Number of subjects: 45
Study 19660844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of whey protein
Number of subjects: 45
Study 19660844 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of whey protein combined with 5 g of essential amino acids
Number of subjects: 45
Study 18498918 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitron (test formulation)
Number of subjects: 34
Study 18498918 — intervention group
Group type: COMPARATOR
Intervention: LosecA (reference formulation)
Number of subjects: 34
Study 18498918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 34
Study 15916502 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7705
Study 15916502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 12590203 — intervention group
Group type: EXPERIMENTAL
Intervention: ProOsteon 200 (coralline hydroxyapatite)
Number of subjects: 29
Study 12590203 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest graft (control)
Number of subjects: 29
Study 10573278 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 112
Study 10573278 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 112
Study 8763463 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 12 weeks
Number of subjects: 195
Study 8763463 — intervention group
Group type: COMPARATOR
Intervention: 200 mg itraconazole daily for 12 weeks
Number of subjects: 195
Study 2038367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 281
Study 2038367 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 281
Study 6337228 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin treatment
Number of subjects: 21
Study 6337228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gentamicin)
Number of subjects: 21
Study 28622082 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-needling combined with 10% TCA cream
Number of subjects: 0
Study 28622082 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser
Number of subjects: 0
Study 28887670 — intervention group
Group type: EXPERIMENTAL
Intervention: First generation steerable robotic catheter, version 1.0 (group 1)
Number of subjects: 21
Study 28887670 — intervention group
Group type: EXPERIMENTAL
Intervention: New version steerable robotic catheter, version 1.1 (group 2)
Number of subjects: 21
Study 28887670 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 21
Study 27128538 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen during and two hours after surgery
Number of subjects: 1386
Study 27128538 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen during and two hours after surgery
Number of subjects: 1386
Study 24679046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU) administered twice a day for 7.5 days
Number of subjects: 220
Study 24679046 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice a day for 7.5 days
Number of subjects: 220
Study 22223814 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug company advertisements
Number of subjects: 544
Study 22223814 — intervention group
Group type: COMPARATOR
Intervention: Other sources advertisements
Number of subjects: 544
Study 22223814 — intervention group
Group type: COMPARATOR
Intervention: Logo-free advertisement
Number of subjects: 544
Study 20649443 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilator
Number of subjects: 75
Study 20649443 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal dilator
Number of subjects: 75
Study 20649443 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatz dilator
Number of subjects: 75
Study 17656469 — intervention group
Group type: EXPERIMENTAL
Intervention: DPC 333 at 5.5 mg/kg daily for 2 weeks in a rat collagen antibody-induced arthritis model
Number of subjects: 1
Study 17656469 — intervention group
Group type: EXPERIMENTAL
Intervention: DPC 333 (oral)
Number of subjects: 1
Study 17656469 — intervention group
Group type: EXPERIMENTAL
Intervention: DPC 333 (oral, single escalating doses)
Number of subjects: 1
Study 15871635 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (900 mg once daily)
Number of subjects: 364
Study 15871635 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (1000 mg three times daily)
Number of subjects: 364
Study 11799030 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur (carbon dioxide extract tablets, ZE 339) one tablet, four times daily for two weeks
Number of subjects: 125
Study 11799030 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine, one tablet in the evening for two weeks
Number of subjects: 125
Study 11799030 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 125
Study 9584823 — intervention group
Group type: EXPERIMENTAL
Intervention: No glove change with manual placental delivery (Group A)
Number of subjects: 108
Study 9584823 — intervention group
Group type: EXPERIMENTAL
Intervention: No glove change with expressed placental delivery (Group B)
Number of subjects: 108
Study 9584823 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove change with manual placental delivery (Group C)
Number of subjects: 108
Study 9584823 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove change with expressed placental delivery (Group D)
Number of subjects: 108
Study 9584823 — intervention group
Group type: COMPARATOR
Intervention: Combined no glove change (Groups A and B)
Number of subjects: 108
Study 9584823 — intervention group
Group type: COMPARATOR
Intervention: Combined glove change (Groups C and D)
Number of subjects: 108
Study 9584823 — intervention group
Group type: COMPARATOR
Intervention: Combined manual placental delivery (Groups A and C)
Number of subjects: 108
Study 9584823 — intervention group
Group type: COMPARATOR
Intervention: Combined expressed placental delivery (Groups B and D)
Number of subjects: 108
Study 7658296 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents who attended evening sessions of the drug prevention program
Number of subjects: 1761
Study 7658296 — intervention group
Group type: EXPERIMENTAL
Intervention: Students whose parents completed the survey
Number of subjects: 1761
Study 7658296 — intervention group
Group type: COMPARATOR
Intervention: Students whose parents did not complete a survey
Number of subjects: 1761
Study 2096106 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dimethindene maleate (Fenistil, Tropfen)
Number of subjects: 8
Study 2096106 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8
Study 1015353 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmyocardial Infarction Clinic treatment
Number of subjects: 96
Study 1015353 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated at the clinic)
Number of subjects: 96
Study 30941580 — intervention group
Group type: EXPERIMENTAL
Intervention: HNCP (Head and Neck Cancer Survivor Self-Management Care Plan)
Number of subjects: 109
Study 30941580 — intervention group
Group type: COMPARATOR
Intervention: Information about survivorship
Number of subjects: 109
Study 30941580 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109
Study 28926885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) therapy with energy of 14-16 J/cm²
Number of subjects: 44
Study 28926885 — intervention group
Group type: COMPARATOR
Intervention: Control eye receiving placebo therapy with 0 J/cm²
Number of subjects: 44
Study 25639487 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine mouthwash
Number of subjects: 40
Study 25639487 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 40
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated venous sinus
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct pial venous drainage
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudophlebitic pattern
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous ectasia
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk venous drainage
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhage
Number of subjects: 41
Study 23800872 — intervention group
Group type: EXPERIMENTAL
Intervention: New/worsened NHND
Number of subjects: 41
Study 21639900 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter alone
Number of subjects: 5523
Study 21639900 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter plus reminder call
Number of subjects: 5523
Study 21639900 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letter plus a second reminder and booklet plus a counselor call
Number of subjects: 5523
Study 21639900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5523
Study 19229450 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait trainer exercise
Number of subjects: 56
Study 19229450 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking training over ground
Number of subjects: 56
Study 19229450 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 56
Study 19229450 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 56
Study 16807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT (conjugated equine estrogen 0.625 mg/day for 6 months)
Number of subjects: 36
Study 16807281 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT (17beta‐estradiol gel 0.6 mg/day for 6 months)
Number of subjects: 36
Study 16807281 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 6 months)
Number of subjects: 36
Study 12891248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/day)
Number of subjects: 86
Study 12891248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 86
Study 12891248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with fluvastatin (40 mg/day) and fenofibrate (200 mg/day)
Number of subjects: 86
Study 10848568 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed discrimination task
Number of subjects: 0
Study 10848568 — intervention group
Group type: COMPARATOR
Intervention: Contrast discrimination task
Number of subjects: 0
Study 8950722 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 0
Study 8950722 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 0
Study 1549214 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (10 mg/d)
Number of subjects: 12
Study 1549214 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl (withdrawn after 1 month)
Number of subjects: 12
Study 1549214 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study 2994795 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered closure
Number of subjects: 507
Study 2994795 — intervention group
Group type: COMPARATOR
Intervention: Mass closure
Number of subjects: 507
Study 31519624 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (n=19)
Number of subjects: 86
Study 31519624 — intervention group
Group type: COMPARATOR
Intervention: Observation (n=18)
Number of subjects: 86
Study 29540160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 probiotic for 4 weeks
Number of subjects: 113
Study 29540160 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 113
Study 26983055 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect moxibustion therapy
Number of subjects: 43
Study 26983055 — intervention group
Group type: COMPARATOR
Intervention: Control session (blinded moxibustion smoke and aroma)
Number of subjects: 43
Study 24565387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (2 μg/kg)
Number of subjects: 30
Study 24565387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23107851 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 385
Study 23107851 — intervention group
Group type: COMPARATOR
Intervention: Lay Foot Manipulation (LFM)
Number of subjects: 385
Study 23107851 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care
Number of subjects: 385
Study 20435194 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (oral vasopressin receptor antagonist)
Number of subjects: 4133
Study 20435194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 18076227 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed method (PC) using speed, agility, quickness (SAQ) conditioning method
Number of subjects: 46
Study 18076227 — intervention group
Group type: EXPERIMENTAL
Intervention: Random method (RC) playing supervised small-sided soccer games
Number of subjects: 46
Study 18076227 — intervention group
Group type: COMPARATOR
Intervention: No conditioning (NC)
Number of subjects: 46
Study 16102553 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 380A IUD
Number of subjects: 368
Study 16102553 — intervention group
Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 368
Study 16102553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (IUD and DMPA)
Number of subjects: 368
Study 11876714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis DN-173 010 (three 125 g cups per day of fermented milk)
Number of subjects: 36
Study 11876714 — intervention group
Group type: COMPARATOR
Intervention: Control (fermented milk without bifidobacteria)
Number of subjects: 36
Study 11876714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis DN-173 010
Number of subjects: 36
Study 11876714 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 10215097 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 32
Study 10215097 — intervention group
Group type: COMPARATOR
Intervention: Normal control participants
Number of subjects: 32
Study 8525285 — intervention group
Group type: COMPARATOR
Intervention: 150 micrograms/kg followed by placebo
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg with a clearing dose
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/kg without a clearing dose
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg with a clearing dose
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms/kg without a clearing dose
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms/kg with a clearing dose
Number of subjects: 75
Study 8525285 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 micrograms/kg without a clearing dose
Number of subjects: 75
Study 2145407 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment for elderly patients with grade III or IV retinopathy, congestive heart failure, or cerebral infarction or hemorrhage.
Number of subjects: 0
Study 2145407 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment for elderly patients with established mild hypertension under 80 years of age.
Number of subjects: 0
Study 2145407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic antihypertensive treatment for elderly patients over 80 years of age or those with isolated systolic hypertension.
Number of subjects: 0
Study 394868 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP chemotherapy
Number of subjects: 84
Study 394868 — intervention group
Group type: COMPARATOR
Intervention: CCNU as a single agent
Number of subjects: 84
Study 30734357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal therapy for H. pylori infection (ILTHPI)
Number of subjects: 100